Le Lézard
Classified in: Health
Subjects: PER, WOM, MAT

Shannon Bledsoe Named Executive Director of WCG


SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- WCG is pleased to announce that Shannon Bledsoe has been appointed to Executive Director.

www.wcgcares.org

"I am pleased to have Shannon move into this leadership role as WCG's Executive Director," said Saundra Pelletier, Chair of the WCG Board of Directors.  "WCG has already benefited greatly from Shannon's extensive experience and proven track record in the field of reproductive and sexual health and we look forward to her future contributions as WCG continues to deliver on its mission to educate, empower and enable girls and women."

As Executive Director, Ms. Bledsoe will be responsible for leading overall organizational growth and strategic direction, and overseeing the quality of WCG's programming. She brings nearly 20 years of experience in international development, public health, and reproductive rights to this position, leading programs and platforms for both large and small global non-profit organizations. In these leadership roles, Ms. Bledsoe raised nearly $100 million dollars to support the implementation of global programs. Ms. Bledsoe has designed and managed initiatives supporting women's reproductive health worldwide, and consulted with clients ranging from Yale University to small local organizations on social marketing and addressing barriers to access. Ms. Bledsoe led country platforms in Haiti, Cote d'Ivoire, and the Central African Republic and has worked, lived, and traveled in more than 40 countries. She has an advanced degree from the University of Melbourne, Australia and a BA from the University of California, San Diego.

"Under Saundra Pelletier's leadership since founding the non-profit organization in 2009, WCG has become a major player in the reproductive health care space with innovative programs and partnerships," said Shannon Bledsoe. "I am honored to continue Saundra's exceptional work by growing WCG's partner relationships and programs with the goal of empowering women and girls to make informed choices about their health while increasing access to safe, reliable, and affordable contraceptive options."

About WCG
WCG is an international non-profit organization committed to empowering, educating and enabling girls and women to make informed choices and access critical reproductive health products and services.  WCG's credentials in product introduction have made it a preferred partner of organizations looking to move products from laboratories and manufacturing plants to the women who need them. WCG excels at forming strategic partnerships to introduce and create access to new contraceptive methods around the world. WCG's quality and regulatory department is experienced in the global registration of drugs and devices, and in aiding manufacturers to improve their processes to meet international best practices.   WCG creates options for women when it comes to their reproductive health ? no matter where they live.  For more information, please visit www.wcgcares.org.

Ellen Thomas
VP, Corporate Communications
Phone: +1.718.490.3248
E-mail: [email protected]

 

SOURCE WCG


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: